Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 500 full-time employees. The company went IPO on 2018-03-15. The firm is focused on developing differentiated molecules and combination therapies for people with cancer. The firm involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately five clinical programs that are focused on targets, including TIGIT, PD-1, HIF-2a, adenosine A2a and A2b receptors and CD73. The company is evaluating three antibodies and three small molecules across 13 different clinical studies, including four Phase III studies. The company is developing two investigational anti-TIGIT monoclonal antibodies, which include domvanalimab (Fc-silent) and AB308 (Fc-enabled). HIF-2a is a master transcriptional regulator of multiple genes involved in tumor progression. The firm's investigational products also include etrumadenant and quemliclustat.